1 Min Read
Oct 11 (Reuters) - Fortress Biotech Inc:
* Mustang Bio announces $12.8 million grant to fund Phase 1 trial of CAR T therapy MB-101 in malignant glioma Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.